CADL — Candel Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $187.53m
- $173.39m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -8.24 | -17.7 | -36.1 | -18.8 | -37.9 |
Depreciation | |||||
Non-Cash Items | 2.51 | 6.74 | 14.6 | -13.5 | 3.26 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.513 | 1.77 | -0.876 | 0.071 | -0.525 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -5.18 | -9.07 | -22.2 | -31.4 | -34.2 |
Capital Expenditures | -0.159 | -1.48 | -1.83 | -1.3 | -0.457 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -35.6 | 39.9 | 0 | — | 0.177 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -35.7 | 38.5 | -1.83 | -1.3 | -0.28 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 22 | 0.49 | 71.8 | 20 | -0.121 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -18.9 | 29.9 | 47.7 | -12.7 | -34.6 |